Notes
National Health Service
Reference
NICE. NICE draft guidance recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement. Media Release : 23 Nov 2015. Available from: URL: http://www.nice.org.uk
Rights and permissions
About this article
Cite this article
NICE recommends elosulfase-α for MPS-IVa. PharmacoEcon Outcomes News 742, 37 (2015). https://doi.org/10.1007/s40274-015-2665-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2665-x